Lobe Sciences reaches milestone as it completes production of psilocin analogues

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) CEO Philip Young tells Proactive’s Stephen Gunnion that completing the syntheses of bulk L-130 marks an important step in the validation of its approach to developing novel psilocin analogues.

L-130 is a proprietary form of psilocin, which Young explains is the active component within psilocybin. It was was manufactured in compliance with US current good manufacturing practices (cGMPs) which allows Lobe to export it around the globe. The first Phase 1 study will commence in the Middle East in the next few weeks, he adds.

#ProactiveInvestors #LobeSciences #L-130 #psilocin #psilocybin #CSE #OTCQB

You might like

© 2022 Stockmark.it The Latest StockMarket News and Interviews